Business briefs: Élan, Teva
A buyout offer upsets Elan's post-Tysabri plans, Takeda and Affymax recall Omontys.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Your message:
The e-mail address(es) that you supply to use this service will only be used to send the requested article.